New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
13:38 EDTGILD, NPSP, AMGN, BMY, C, BIIB, ABBV, SHPGShire selects Citi as adviser to prepare for takeover offers, Reuters reports
Shire (SHPG) has hired Citi (C) as an adviser as it prepares for takeover bids, Reuters reports, citing sources. Bankers in the sector believe Shire could be a attractive to Bristol Myers (BMY), Abbvie (ABBV), Gilead (GILD), Biogen (BIIB) or Amgen (AMGN). Reference Link
News For SHPG;C;NPSP;ABBV;BMY;GILD;BIIB;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
August 25, 2015
12:20 EDTCOn The Fly: Top stock stories at midday
Subscribe for More Information
11:12 EDTCNumerous analysts upgrade Bank of America amid market rebound
Subscribe for More Information
09:16 EDTAMGNAmgen to present Repatha data analysis at ESC Congress 2015
Subscribe for More Information
09:03 EDTSHPG, BIIB, ABBVAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
09:02 EDTAMGNAmgen submits NDA for hyperparathyroidism treatment
Subscribe for More Information
07:06 EDTSHPGShire reaches CINRYZE agreement with Sanquin Blood Supply
Subscribe for More Information
August 24, 2015
18:55 EDTSHPGOn The Fly: After Hours Movers
Subscribe for More Information
18:52 EDTSHPGJazz, Celgene, Shire up after USPTO rejects Acorda patent challenge
Subscribe for More Information
13:36 EDTGILD, AMGNBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.
09:45 EDTBMYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Bank of America (BAC) upgraded to Outperform from Market Perform at Keefe Bruyette... Bristol-Myers (BMY) upgraded to Neutral from Underweight at Piper Jaffray... Chevron (CVX) upgraded to Neutral from Underperform at BofA/Merrill... Abercrombie & Fitch (ANF) upgraded to Overweight from Neutral... Nike (NKE) upgraded to Outperform from Market Perform at Telsey Advisory... DreamWorks (DWA) upgraded to Buy from Neutral at B. Riley... Caesarstone (CSTE) upgraded to Overweight from Equal Weight at Barclays... TransAlta (TAC) upgraded to Outperform from Market Perform at BMO Capital... Sarepta (SRPT) upgraded to Overweight from Neutral at Piper Jaffray... AutoZone (AZO) upgraded to Buy from Neutral at BofA/Merrill... Royal Dutch Shell (RDS.A) upgraded to Buy from Hold at Jefferies... Allscripts (MDRX) upgraded to Buy from Hold at Argus... China Unicom (CHU) upgraded to Buy from Hold at Jefferies... Ross Stores (ROST) upgraded to Buy from Neutral at Buckingham.
08:16 EDTBMYBristol-Myers, Pfizer to present new data on Eliquis at ESC Congress 2015
Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) announced that 22 abstracts will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance's commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation and venous thromboembolism patient populations. In addition, data from the AEGEAN study evaluating adherence among NVAF patients further extends the Alliance's commitment to patient care.
07:08 EDTBMYBristol-Myers upgraded to Neutral from Underweight at Piper Jaffray
Subscribe for More Information
07:05 EDTCCitigroup volatility at high end of range
Citigroup August weekly call option implied volatility is at 39, October is at 30; compared to its 52-week range of 14 to 30, suggesting large near term price movement.
August 23, 2015
12:35 EDTBMYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
16:01 EDTCOptions Update; August 21, 2015
Subscribe for More Information
09:38 EDTSHPG, BIIBUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
August 20, 2015
16:34 EDTGILDGilead MAA for HIV regimen has been fully validated by EMA
Gilead Sciences announced that the company's Marketing Authorization Application, MAA, for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 mg has been fully validated and is now under evaluation by the European Medicines Agency, EMA. Emtricitabine and tenofovir alafenamide are marketed by Gilead Sciences and rilpivirine is marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The data included in the application support the use of R/F/TAF for the treatment of HIV-1 infection in adults and pediatric patients 12 years and older. "With this validation, R/F/TAF is now the third TAF-based filing under review by the EMA as we advance a portfolio of new treatment options that may offer high efficacy and favorable safety profiles," said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. "The R/F/TAF filing also represents the next step in our collaboration with Janssen to develop HIV treatments that potentially meet the diverse needs of people living with HIV."
16:24 EDTBIIBBiogen reports 8.1% passive stake in Applied Genetic
Subscribe for More Information
06:07 EDTCSamsung Bioepis picks Citi, Goldman as lead managers for IPO, Reuters says
Samsung Bioepis has selected Citigroup (C) and Goldman Sachs (GS) as the lead managers for its planned listening on Nasdaq next year, a source tells Reuters. Morgan Stanley (MS) and Credit Suisse (CS) will also take part in the listing for Samsung's (SSNLF) biosimilar drug development arm, the source says. Reference Link
06:01 EDTBMYBristol-Myers announces Canadian approval of Daklinza
Subscribe for More Information
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use